KeyBanc lowered the firm's price target on Schrodinger to $20 from $25 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup is largely positive, with beats likely across the group. That said, KeyBanc thinks most companies will reiterate their full-year guidance given the uncertain macro. Thematically, it believes healthcare systems are continuing to see good utilization, supporting capex/ software spend, and Pharma digital advertising environment remains choppy.
